Clinic Fukuoka News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LOS ANGELES: Japan’s Kyushu Certified Special Committee for Regenerative Medicine, Appropriate Opinion on Treatment Plan for COVID-19 Sequelae Using Autologous Adipose-derived Mesenchymal Stem Cells The patented technology developed by Korea’s Biostar Stem Cell Research Institute is scheduled to start in late December at the Japanese medical corporation Yesunghoe Trinity Clinic Fukuoka Stem cell therapy developed in Korea to treat sequelae resulting from COVID-19 infection is being launched for the first time in Japan. Recently, the risk is rapidly increasing with patients from all over the world, and the third wave of the pandemic has started. Nature Cell, a revolutionary stem cell bio company announced on the 8th of December that Yesunghoe Trinity Clinic Fukuoka, a Japanese affiliate hospital received the approval from the Certified Special Committee for Regenerative Medicine for the treatment of COVID-19 sequelae using fat-derived mesenchymal stem cells.

United statesHong kongJane shinMinistry of healthCommittee for renewable healthSafety of renewable healthClinical researchFemoral head avascular necrosis local clinical researchStemcell bio incAlzheimer iv clinical research in progressCell processing centerRotator muscle disease local clinical researchJournal of american medical associationCertified special committee for regenerative medicineBiostar stem cell research instituteWorld health organization